C5 and atypical hemolytic-uremic syndrome: Eculizumab, a monoclonal antibody binding C5, inhibiting its cleavage, and thus preventing formation of C5b-9, is used to treat aHUS and some cases of lupus nephritis, C3 glomerulonephritis, dense deposit disease, IgA nephropathy, and transplant rejection (10–17).